Burning Rock Biotech (BNR) Return on Capital Employed (2020 - 2026)

Burning Rock Biotech (BNR) has reported Return on Capital Employed for 7 consecutive years, with 10.15% the latest figure, recorded in Q1 2026.

• In Q1 2026, Return on Capital Employed rose 2971.0% year-over-year to 10.15%; the TTM figure through Mar 2026 stood at 10.15% (up 2971.0% YoY), while the FY2025 annual figure was 9.34%, up 4095.0% from the prior year.
• Return on Capital Employed came in at 10.15% for Q1 2026 at Burning Rock Biotech, down from 9.56% in the prior quarter.
• The five-year high for Return on Capital Employed was 9.56% in Q4 2025, with the low at 83.32% in Q4 2022.
• Average Return on Capital Employed over 5 years is 56.27%, with a median of 59.49% recorded in 2024.
• Across the five-year window, Return on Capital Employed tumbled 4322 bps in 2022 and surged 5427 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 83.32% in 2022, then increased by 2 bps to 81.49% in 2023, then surged by 36 bps to 52.27% in 2024, then soared by 82 bps to 9.56% in 2025, then decreased by 6 bps to 10.15% in 2026.
• According to Business Quant data, Return on Capital Employed over the past three periods registered 10.15%, 9.56%, and 21.03% for Q1 2026, Q4 2025, and Q3 2025 respectively.